ABL1 and acute lymphoblastic leukemia: Early published data have shown that in a Ph+ ALL pediatric population, imatinib combined with standard chemotherapy could reverse the negative impact on prognosis conferred by the presence of the BCR‐ABL1 fusion transcript, resulting in a significant improvement in the probability of event-free survival (EFS) (15, 16).